Cardiac safety and efficacy of concomitant liposomal doxorubicin, docetaxel, and trastuzumab as neoadjuvant therapy in HER2-overexpressing breast cancer: A retrospective analysis

被引：0
|
作者：
Brunner, Christine
Jaeger, Thomas
Suppan, Christoph
Mueller-Holzner, Elisabeth
Jasarevic, Zerina
Balic, Marija
Goebel, Georg
Marth, Christian
Stoeger, Herbert
Samonigg, Hellmut
Hubalek, Michael
Lang, Alois
机构：
[1] Dept Gynecol & Obstet, Innsbruck, Austria
[2] LKH Feldkirch, Feldkirch, Austria
[3] Med Univ Graz, Dept Internal Med, Graz, Austria
[4] Med Univ Innsbruck, Dept Obstet & Gynecol, A-6020 Innsbruck, Austria
[5] Breast Canc Ctr Vorarlberg, Feldkirch, Austria
[6] Med Univ Graz, Graz, Austria
[7] Med Univ Innsbruck, Dept Med Stat Informat & Hlth Oecon, A-6020 Innsbruck, Austria
[8] Med Univ Graz, Dept Med Oncol, Graz, Austria
[9] Med Univ Innsbruck, Dept Obstet & Gynecol, A-6020 Innsbruck, Austria
[10] Acad Teaching Hosp, Feldkirch, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
583
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Effect of dasatinib on the activity of trastuzumab in HER2-overexpressing breast cancer cells
    Seoane, S.
    Montero, J. C.
    Pandiella, A.
    Ocana, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] Target Therapy in HER2-Overexpressing Breast Cancer Patients
    Amodio, Rosalba
    Zarcone, Maurizio
    Cusimano, Rosanna
    Campisi, Ildegarda
    Dolcemascolo, Cecilia
    Traina, Adele
    Agostara, Biagio
    Romano, Nino
    OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY, 2011, 15 (06) : 363 - 367
  • [23] A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer
    Montemurro, F
    Choa, G
    Faggiuolo, R
    Donadio, M
    Minischetti, M
    Durando, A
    Capaldi, A
    Vietti-Ramus, G
    Alabiso, O
    Aglietta, M
    ONCOLOGY, 2004, 66 (01) : 38 - 45
  • [24] Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study
    Wang, Haoqi
    Li, Yuntao
    Qi, Yixin
    Zhao, Erbao
    Kong, Xiangshun
    Yang, Chao
    Yang, Qiqi
    Zhang, Chengyuan
    Liu, Yueping
    Song, Zhenchuan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [25] Capecitabine combined with trastuzumab in the therapy of intensively pretreated HER2-overexpressing metastatic breast cancer (MBC).
    Bangemann, N
    Kuhle, A
    Ebert, A
    Bühler, H
    Schaller, G
    ANNALS OF ONCOLOGY, 2000, 11 : 143 - 143
  • [26] Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer
    Kim, M. M.
    Allen, P.
    Gonzalez-Angulo, A. M.
    Woodward, W. A.
    Meric-Bernstam, F.
    Buzdar, A. U.
    Hunt, K. K.
    Kuerer, H. M.
    Litton, J. K.
    Hortobagyi, G. N.
    Buchholz, T. A.
    Mittendorf, E. A.
    ANNALS OF ONCOLOGY, 2013, 24 (08) : 1999 - 2004
  • [27] Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study
    Anton, A.
    Ruiz, A.
    Plazaola, A.
    Calvo, L.
    Segui, M. A.
    Santaballa, A.
    Munoz, M.
    Sanchez, P.
    Miguel, A.
    Carrasco, E.
    Lao, J.
    Camps, J.
    Alfaro, J.
    Antolin, S.
    Camara, M. C.
    ANNALS OF ONCOLOGY, 2011, 22 (01) : 74 - 79
  • [28] Efficacy and safety of trastuzumab combined with chemotherapy for first-line treatment and beyond progression of HER2-overexpressing advanced breast cancer
    Li, Huiping
    Shao, Bin
    Yan, Yin
    Song, Guohong
    Liu, Xiaoran
    Wang, Jing
    Liang, Xu
    CHINESE JOURNAL OF CANCER RESEARCH, 2016, 28 (03) : 330 - 338
  • [29] TBCRC 006: A multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer
    Chang, J. C. N.
    Mayer, I. A.
    Forero-Torres, A.
    Nanda, R.
    Goetz, M. P.
    Rodriguez, A. A.
    Pavlick, A. C.
    Wang, T.
    Hilsenbeck, S. G.
    Gutierrez, C.
    Schiff, R.
    Osborne, C. K.
    Rimawi, M. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] Efficacy and safety of trastuzumab combined with chemotherapy for first-line treatment and beyond progression of HER2-overexpressing advanced breast cancer
    Huiping Li
    Bin Shao
    Yin Yan
    Guohong Song
    Xiaoran Liu
    Jing Wang
    Xu Liang
    ChineseJournalofCancerResearch, 2016, 28 (03) : 330 - 338
12345